A new analysis suggests that the doses of rodatristat ethyl — an investigational therapy for pulmonary arterial hypertension…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
An updated application has been filed with the U.S. Food and Drug Administration (FDA), again asking that LIQ861Â be approved…
By screening thousands of potential candidates, researchers have identified a compound, called AG1296, that may be useful for the treatment of…
Activation of a protein called aryl hydrocarbon receptor (AHR) is essential for the development of pulmonary arterial hypertension (PAH),…
Treatment with a fungus called Ophiocordyceps sinensis eased disease signs and improved survival in a rat model of pulmonary…
Treatment with the investigational medication levosimendan was found to improve exercise tolerance, and some parameters related to heart function, in…
Experts will discuss how the COVID-19 pandemic has affected people living with pulmonary hypertension and other rare respiratory…
Acute pulmonary hypertension (aPH) is frequent and linked with a higher risk of mortality in people who are severely ill…
People with pulmonary hypertension are less likely to be referred to exercise therapy if they are of lower socioeconomic…
PhaseBio Pharmaceuticals‘s investigational therapy pemziviptadil (PB1046) showed a good safety…
The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial…
Enrollment is resuming for the VIP clinical trial, which is evaluating PhaseBio Pharmaceuticals‘ investigational therapy pemziviptadil (PB1046) in people…